Roivant Sciences Ltd. (NASDAQ:ROIV) Short Interest Up 45.9% in April

Roivant Sciences Ltd. (NASDAQ:ROIV) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 45,130,000 shares, a growth of 45.9% from the March 31st total of 30,930,000 shares. Based on an average daily volume of 7,280,000 shares, the short-interest ratio is currently 6.2 days. Currently, 8.2% of the shares of the company are short sold.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Piper Sandler assumed coverage on shares of Roivant Sciences in a report on Friday, January 5th. They set an “overweight” rating and a $20.00 price target for the company. Wolfe Research assumed coverage on shares of Roivant Sciences in a report on Thursday, February 15th. They set an “outperform” rating and a $17.00 price target for the company. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Roivant Sciences from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Truist Financial reiterated a “buy” rating and set a $23.00 price target on shares of Roivant Sciences in a report on Monday, March 25th. Finally, Bank of America lifted their price target on shares of Roivant Sciences from $11.00 to $12.00 and gave the stock a “neutral” rating in a report on Tuesday, January 2nd. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, Roivant Sciences has an average rating of “Moderate Buy” and an average target price of $16.90.

Roivant Sciences Trading Up 1.4 %

ROIV traded up $0.15 during trading on Friday, hitting $11.03. 3,109,700 shares of the company’s stock were exchanged, compared to its average volume of 6,612,257. The company has a current ratio of 27.79, a quick ratio of 27.79 and a debt-to-equity ratio of 0.06. Roivant Sciences has a 1 year low of $8.06 and a 1 year high of $13.24. The stock has a 50 day moving average price of $10.92 and a 200 day moving average price of $10.37. The firm has a market cap of $8.89 billion, a P/E ratio of 2.12 and a beta of 1.34.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Tuesday, February 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.07. Roivant Sciences had a net margin of 3,624.14% and a negative return on equity of 33.38%. The company had revenue of $37.14 million during the quarter, compared to the consensus estimate of $30.72 million. As a group, analysts expect that Roivant Sciences will post -1.36 EPS for the current fiscal year.

Insiders Place Their Bets

In other Roivant Sciences news, COO Eric Venker sold 96,950 shares of the firm’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $10.92, for a total transaction of $1,058,694.00. Following the transaction, the chief operating officer now directly owns 532,207 shares of the company’s stock, valued at approximately $5,811,700.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Roivant Sciences

Several institutional investors have recently bought and sold shares of ROIV. FNY Investment Advisers LLC acquired a new position in shares of Roivant Sciences during the fourth quarter worth $33,000. Headlands Technologies LLC acquired a new position in shares of Roivant Sciences during the fourth quarter worth $36,000. Allspring Global Investments Holdings LLC acquired a new position in shares of Roivant Sciences during the third quarter worth $44,000. Covestor Ltd lifted its position in shares of Roivant Sciences by 165,040.0% during the third quarter. Covestor Ltd now owns 8,257 shares of the company’s stock worth $96,000 after purchasing an additional 8,252 shares in the last quarter. Finally, Premier Path Wealth Partners LLC acquired a new position in shares of Roivant Sciences during the first quarter worth $126,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.